PTC Therapeutics, Inc.

527 articles with PTC Therapeutics, Inc.

• PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

  5/20/2022

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec; PTC-AADC) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

• PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results

  5/3/2022

  PTC Therapeutics, Inc. announced a corporate update and financial results for the first quarter ending March 31, 2022.

• PTC Therapeutics to Participate at Upcoming Investor Conferences - Apr 29, 2022

  4/29/2022

  PTC Therapeutics, Inc. announced that management will present a company overview at the following conferences.

• PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results

  4/19/2022

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tuesday, May 3, at 4:30 p.m. ET .

• PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program

  4/14/2022

  PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) with the Committee for Advanced Therapies (CAT).

• PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 08, 2022

  4/8/2022

  PTC Therapeutics, Inc. announced that on April 8, 2022, the company approved non-statutory stock options to purchase an aggregate of 86,130 shares of its common stock and 33,125 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 96 new employees.

• PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease

  3/30/2022

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington's disease (HD). PIVOT-HD is a global trial starting in the United States.

• PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference

  3/11/2022

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in Duchenne muscular dystrophy (DMD) at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 13-16 in Nashville, Tenn. and virtually.

• PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

  2/22/2022

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2021.

• PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results

  2/8/2022

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and year-end 2021 financial results and provide an update on the company's business and outlook on Tuesday, Feb. 22 , at 4:30 p.m. ET .

• FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy

  1/25/2022

  PTC Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted priority review of a supplemental new drug application for Evrysdi® to expand the indication to include pre-symptomatic infants under 2 months old with spinal muscular atrophy.

• PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

  1/18/2022

  PTC Therapeutics, Inc. announced the launch of the eighth annual STRIVE™ awards program for Duchenne muscular dystrophy.

• 

  BioSpace Movers & Shakers, Jan. 14

  1/14/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 13, 2022

  1/13/2022

  PTC Therapeutics, Inc. announced that on Jan. 7, 2022, the company approved non-statutory stock options to purchase an aggregate of 18,255 shares of its common stock and 10,675 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 26 new employees.

• PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program

  1/13/2022

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the company's 2022 Talent Pipeline Program, a one-year, global initiative designed to provide recent college graduates with high-quality, real-world opportunities at work.

• PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference

  1/10/2022

  PTC Therapeutics, Inc. will present an update on its commercial progress and R&D pipeline at the 40th Annual J.P. Morgan Healthcare Conference , Monday Jan. 10th at 7:30am EST. Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, will provide an update on 2021 accomplishments and highlight upcoming potential value-creating milestones.

• Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil

  1/4/2022

  PTC Therapeutics, Inc. announced that Waylivra™ has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED in Brazil.

• PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

  1/3/2022

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Monday, Jan. 10, at 7:30 a.m. EST.

• Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform

  12/20/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the Nature Communications publication characterizing the novel splicing mechanism induced by compounds identified from the Huntington Disease (HD) program.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 02, 2021

  12/2/2021

  PTC Therapeutics, Inc. announced that on Nov. 29, 2021, the company approved non-statutory stock options to purchase an aggregate of 83,750 shares of its common stock and 21,550 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 49 new employees.